S. Chabaud(1,2), P. Girardd(1,2), P. Nony(1,2), JP. Boissel(1,2) and THERMOS group(3) Use of a Therapeutic Model for Simulating Phase III Clinical Trials of a New Bradycardic Agent
|
A.C. Davison Bootstrap Methods
|
Stephen Duffull(1), Leon Aarons(1) and the THERMOS group(2). Development of a Linked Pharmacokinetic and Pharmacodynamic Simulation Model for Ivabradine in Healthy Volunteers
|
Gilles Freyer(1), Brigitte Tranchand(2), Blandine Ligneau(1), Claude Ardiet(2), Pierre-Jean Souquet(3), Isabelle Court-Fortune(3), Robert Riou(3), Paul Rebattu(4), Véronique Trillet-Lenoir(1,6), Jean-Pierre Boissel(5,6), Pascal Girard(5,6). Population Pharmacokinetic Parameters of Doxorubicin, Ifosamide and Etoposide in Small Cell Lung Cancer Patients
|
R. Gomeni(1), I. Cognet(1) and F. Servin(2) Population Analysis (NONMEM) using a Concentration-to-Event Approach to Evaluate the Propofol Anaesthesia Induction Strategy using a Target Controlled Infusion (TCI) System: Diprifusor TCI
|
R Jelliffe(1), A Schumitzky(1), D Bayard(1), M Van Guilder(1), X Wang(1), M Milman(1), S Leonov(1), R Leary(2), P Maire(3), X Barbaut(3), and S Lecoq(3) Population PK/PD Modeling and Optimal Drug Dosage
|
E. Niclas Jonsson1,2 and Lewis B. Sheiner2 Quantifying Non-Standard Evidence for Drug Approval
|
Byron Jones Constructing optimal designs for fitting pharmacokinetic models
|
MO Karlsson, RC Schoemaker, B Kemp, A Cohen, J van Gerven, M Danhof A Pharmacodynamic Markov Mixed Effect Model for Temazepams Effect on Sleep
|
Peter A. Milligan1, Scott F. Marshall1, Mats O. Karlsson2 A Population Pharmacokinetic and Pharmacodynamic Analysis of Sildenafil Phase III Data
|
Per Olsson Gisleskog1 & Mats O Karlsson2 The Use of Priors in NONMEM Population Analysis
|
M. Tod Robust optimal design for hyperparameter estimation
|
Janet R. Wade(1) and Mats O. Karlsson(2) Combining PK and PD data during population PK/PD analysis
|
Ulrika Wählby, E. Niclas Jonsson and Mats O. Karlsson Determination of Inclusion Frequency of False Covariate Relationships in Population Modelling
|
A. Mallet Non-parametric methods for continuous and binary variables in population PK/PD.
|
M. Looby Characterisation of dose response in early drug development: A case study
|
Barry Jones Pharmacogenetics
|